title: Pharmacogenetics and immunosuppressive drugs.
abstract: Several candidate genes have been proposed as potential biomarkers for altered pharmacodynamics or pharmacokinetics of immunosuppressive drugs. However, there is usually only limited clinical evidence substantiating the implementation of biomarkers into clinical practice. Testing for thiopurine-S-methyltransferase polymorphisms has been put into routine clinical use quite widely, while the other pharmacogenetic tests are much less frequently used. Relatively good evidence appeared for tacrolimus-related biomarkers; thus, their utilization may be envisaged in the near future. Although the biomarkers related to mycophenolate, sirolimus or other drugs in the therapeutic class may be promising, further research is necessary to provide more robust evidence. The present review focuses on immunosuppressive drugs, excluding biological treatment.
authors.affiliation: Department of Pharmacology, First Faculty of Medicine and General Teaching Hospital, Charles University in Prague, Albertov 4, CZ-128 00 Prague 2, Czech Republic.
authors.forename: Karolína
authors.initials: K
authors.lastname: Hronová
authors.forename: Martin
authors.initials: M
authors.lastname: Šíma
authors.forename: Svatopluk
authors.initials: S
authors.lastname: Světlík
authors.forename: Olga
authors.initials: O
authors.lastname: Matoušková
authors.forename: Ondřej
authors.initials: O
authors.lastname: Slanař
mesh_terms: D000818:Animals; D005819:Genetic Markers; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D008780:Methyltransferases / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic
chemical_list: D005819:Genetic Markers; D007166:Immunosuppressive Agents; D008780:Methyltransferases; C022745:thiopurine methyltransferase
keywords: donor; immunosuppressants; pharmacodynamics; pharmacogenomics; pharmacokinetics; recipient